28 2月 2022 by admin in UncategorizedComments Design Therapeutics Announces FDA Clearance of Investigational New Drug Application for First GeneTACTM Molecule for Friedreich Ataxia
16 2月 2022 by admin in UncategorizedComments Walking Fish Therapeutics Closes $73 Million Series A Financing
08 2月 2022 by admin in UncategorizedComments Arcellx Announces Closing of Initial Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares
02 2月 2022 by admin in UncategorizedComments Syros Receives FDA Orphan Drug Designation for Tamibarotene for the Treatment of MDS
01 2月 2022 by admin in UncategorizedComments Design Therapeutics Appoints Drug Development Expert, Jae Kim, M.D., as Chief Medical Officer
